SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. Show more

777 W 41st St., Miami Beach, FL, 33140, United States

Biotechnology

Healthcare

Market Cap

285.2M

52 Wk Range

$1.85 - $6.60

Previous Close

$3.73

Open

$3.76

Volume

150,919

Day Range

$3.65 - $3.77

Enterprise Value

184.8M

Cash

107.4M

Avg Qtr Burn

-14.27M

Insider Ownership

0.84%

Institutional Own.

92.04%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
SAB-142 Details Stage 3 Type 1 Diabetes (T1D)	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SAB-142 (Anti-Thymocyte Globulin) Details Stage 3 Type 1 Diabetes (100 Days To 2 Years From Diagnosis)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.